Covey D F, Hood W F, McMullan P C
Biochem Pharmacol. 1986 May 15;35(10):1671-4. doi: 10.1016/0006-2952(86)90321-7.
The inactivation of human placental aromatase by 17 alpha-ethynyl-10 beta-hydroperoxy-17 beta-hydroxy-4-estren-3-one (SCH 10015) was investigated. In either the presence or absence of added NADPH, SCH 10015 (Ki = 41 microM) caused a time-dependent loss of aromatase activity (e.g. 50% loss after 20 min with 20 microM SCH 10015). Evidence for the oxidation of an active site sulfhydryl group as the molecular basis for SCH 10015 inactivation is presented. The contraceptive 17 alpha-ethynyl-substituted 19-nor steroids, norethisterone (Ki = 48 microM) and norethynodrel (Ki = 38 microM), were evaluated and found not to inactivate aromatase, suggesting that the potential conversion of either compound to SCH 10015 did not occur to a significant extent in these microsomal incubations. It is speculated that the previously observed potent contraceptive effects of SCH 10015 may have been the result of irreversible inhibition of estrogen biosynthesis.
研究了17α-乙炔基-10β-氢过氧-17β-羟基-4-雌甾烯-3-酮(SCH 10015)对人胎盘芳香化酶的失活作用。无论是否添加NADPH,SCH 10015(Ki = 41μM)都会导致芳香化酶活性随时间丧失(例如,20μM SCH 10015作用20分钟后活性丧失50%)。本文提供了活性位点巯基氧化作为SCH 10015失活分子基础的证据。对避孕药17α-乙炔基取代的19-去甲甾体炔诺酮(Ki = 48μM)和异炔诺酮(Ki = 38μM)进行了评估,发现它们不会使芳香化酶失活,这表明在这些微粒体孵育中,这两种化合物向SCH 10015的潜在转化并未显著发生。据推测,先前观察到的SCH 10015的强效避孕作用可能是雌激素生物合成受到不可逆抑制的结果。